{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mulamba C"],"funding":["European & Developing Countries Clinical Trials Partnership (EDCTP)"],"pagination":["1589061"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12460233"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16"],"pubmed_abstract":["Transmission-blocking vaccines are among the novel tools under development for malaria control and elimination. Understanding the human immune response to the sexual stages of <i>Plasmodium falciparum</i> is essential for progressing transmission-blocking vaccine development. A serosurvey was conducted in Tanzania, from May to August 2022 among 290 participants, consisting of 114 children (5-12 years), 44 adolescents (13-17 years), and 132 adults (18-45 years). The participants were tested for malaria parasites using quantitative polymerase chain reaction, and standardized enzyme-linked immunosorbent assays were performed to detect the presence of IgG antibodies against transmission-blocking target antigens-Pfs230D1M, Pfs48/45, and Pfs25. A set of 10 plasma samples that were reactive to Pf"],"journal":["Frontiers in immunology"],"pubmed_title":["Seroprevalence of antibodies to &lt;i&gt;Plasmodium falciparum&lt;/i&gt; transmission-blocking target proteins Pfs230D1M and Pfs48/45 in Tanzanian populations of diverse malaria transmission intensity."],"pmcid":["PMC12460233"],"funding_grant_id":["RIA2016V-1649"],"pubmed_authors":["Mulamba C","Miura K","Long CA","Mtaka I","Kamage J","Williams C","Lazaro LO","Kreppel K","Mekhaiel D","Nkumama I","Odufuwa OG","Olotu AI","Kalinga WF"],"additional_accession":[]},"is_claimable":false,"name":"Seroprevalence of antibodies to &lt;i&gt;Plasmodium falciparum&lt;/i&gt; transmission-blocking target proteins Pfs230D1M and Pfs48/45 in Tanzanian populations of diverse malaria transmission intensity.","description":"Transmission-blocking vaccines are among the novel tools under development for malaria control and elimination. Understanding the human immune response to the sexual stages of <i>Plasmodium falciparum</i> is essential for progressing transmission-blocking vaccine development. A serosurvey was conducted in Tanzania, from May to August 2022 among 290 participants, consisting of 114 children (5-12 years), 44 adolescents (13-17 years), and 132 adults (18-45 years). The participants were tested for malaria parasites using quantitative polymerase chain reaction, and standardized enzyme-linked immunosorbent assays were performed to detect the presence of IgG antibodies against transmission-blocking target antigens-Pfs230D1M, Pfs48/45, and Pfs25. A set of 10 plasma samples that were reactive to Pf","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-03T21:40:40.891Z","creation":"2026-05-02T03:08:08.433Z"},"accession":"S-EPMC12460233","cross_references":{"pubmed":["41019048"],"doi":["10.3389/fimmu.2025.1589061"]}}